Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
entities : Novartis ag save search
Chinook Therapeutics Enters into Agreement to be Acquired by Novartis AG
Published: 2023-06-12 (Crawled : 06:00) - globenewswire.com
NVS | $94.36 1.93% 0.0% 2.3M
|
Health Technology
|
| O: -0.16%
H: 0.11%
C: -0.76%
KDNY | $40.39 0.22% -0.17% 0
|
Health Technology
|
| O: 57.44%
H: 0.98%
C: 0.55%
novartis therapeutics acquired agreement
Voyager Therapeutics Reports Fourth Quarter and Full Year 2021 Financial and Operating Results
Published: 2022-03-08 (Crawled : 17:00) - voyagertherapeutics.com
NVS | $94.36 1.93% 0.0% 2.3M
|
Health Technology
|
| O: -4.98%
H: 0.0%
C: 0.0%
VYGR | $7.5 -0.66% -0.67% 520K
|
Health Technology
|
| O: 31.15%
H: 19.58%
C: 9.17%
therapeutics report results
Voyager Therapeutics Announces License Option Agreement with Novartis for Target-Specific Access to Next-Generation TRACER™ AAV Capsids for Gene Therapy Programs
Published: 2022-03-08 (Crawled : 07:00) - globenewswire.com
NVS | $94.36 1.93% 0.0% 2.3M
|
Health Technology
|
| O: -4.98%
H: 0.0%
C: 0.0%
VYGR | $7.5 -0.66% -0.67% 520K
|
Health Technology
|
| O: 31.15%
H: 19.58%
C: 9.17%
trace novartis aav capsids gene therapy program license therapeutics therapy
Novartis strengthens immunotherapy pipeline with option, collaboration and license agreement with BeiGene for TIGIT inhibitor ociperlimab
Published: 2021-12-20 (Crawled : 23:00) - globenewswire.com
NVS | $94.36 1.93% 0.0% 2.3M
|
Health Technology
|
| O: -1.03%
H: 0.24%
C: -0.15%
BGNE | $129.51 -1.86% -1.89% 300K
|
Health Technology
|
| O: 8.83%
H: 0.11%
C: -4.16%
novartis license immunotherapy therapy collaboration
Novartis Kisqali® Phase III NATALEE trial meets primary endpoint at interim analysis demonstrating clinically meaningful benefit in broad population of patients with early breast cancer
Published: 2023-03-27 (Crawled : 06:00) - globenewswire.com
PFE A | $26.0 2.4% -0.15% 38M
|
Health Technology
|
| O: 0.37%
H: 0.2%
C: -0.79%
NVS | $94.36 1.93% 0.0% 2.3M
|
Health Technology
|
| O: 6.51%
H: 1.75%
C: 1.4%
kisqali breast cancer novartis trial
Clostridium Diagnostics Market to grow at a CAGR of 13.69% from 2022 to 2027, Driven by the growing prevalence of CDI - Technavio
Published: 2023-03-27 (Crawled : 11:00) - prnewswire.com
AZNCF | News | $138.24 -4.19% 800
|
Health Technology
|
| O: 0.55%
H: 1.46%
C: -0.08%
TMO | News | $544.78 0.6% 0.0% 1.7M
|
Health Technology
|
| O: 0.99%
H: 0.78%
C: -0.37%
NVS | $94.36 1.93% 0.0% 2.3M
|
Health Technology
|
| O: 6.51%
H: 1.75%
C: 1.4%
TRIB | $1.81 -3.72% -3.87% 5.7K
|
Health Technology
|
| O: 1.6%
H: 0.0%
C: -6.32%
AZN | News | $68.56 0.29% 0.29% 4.7M
|
Health Technology
|
| O: 1.46%
H: 0.53%
C: -0.25%
growing diagnostics market
NewAmsterdam Pharma Announces the Appointment of Juliette Audet as Chief Business Officer
Published: 2024-04-01 (Crawled : 12:00) - globenewswire.com
NAMS | $19.98 2.78% 2.7% 140K
|
n/a
|
| O: 6.23%
H: 2.77%
C: -10.21%
NVS | $94.36 1.93% 0.0% 2.3M
|
Health Technology
|
| O: 0.47%
H: 0.23%
C: -0.99%
pharma business
Novartis initiates new USD 15 billion share buyback highlighting confidence in growth and pipeline
Published: 2021-12-16 (Crawled : 09:00) - biospace.com/
NVSEF | $93.6375 6.88% 82K
|
Health Technology
|
| O: 6.92%
H: 0.0%
C: 0.0%
NVS | $94.36 1.93% 0.0% 2.3M
|
Health Technology
|
| O: 5.97%
H: 0.0%
C: 0.0%
novartis growth
Insights on the Advanced Therapy Medicinal Products Global Market to 2027 - Featuring Bluebird Bio, Celgene and Gilead Lifesciences Among Others
Published: 2021-04-26 (Crawled : 14:00) - prnewswire.com
NVS | $94.36 1.93% 0.0% 2.3M
|
Health Technology
|
| O: -0.17%
H: 0.11%
C: -0.35%
VCEL | $43.74 -0.27% -0.27% 520K
|
Health Technology
|
| O: 1.11%
H: 6.59%
C: 6.31%
QURE | $4.68 -0.64% -0.64% 550K
|
Health Technology
|
| O: 5.7%
H: 4.95%
C: 2.43%
BLUE | $1.02 7.03% 6.11% 8.2M
|
Health Technology
|
| O: 1.19%
H: 2.0%
C: 1.69%
therapy
Voyager Therapeutics to Receive $25 Million Payment for License of Next-Generation AAV Capsids for Multiple Neurologic Disease Targets
Published: 2023-03-06 (Crawled : 12:00) - ir.voyagertherapeutics.com
NVSEF | $93.6375 6.88% 82K
|
Health Technology
|
| O: 2.04%
H: 0.0%
C: 0.0%
NVS | $94.36 1.93% 0.0% 2.3M
|
Health Technology
|
| O: 0.34%
H: 0.76%
C: -0.06%
VYGR | $7.5 -0.66% -0.67% 520K
|
Health Technology
|
| O: 5.47%
H: 5.45%
C: 3.24%
disease license therapeutics payment
Erasca Announces Publication of Promising Clinical Data Supporting the Therapeutic Potential of Naporafenib in Combination with Trametinib in NRAS-Mutant Melanoma
Published: 2023-04-25 (Crawled : 15:00) - biospace.com/
NVSEF | $93.6375 6.88% 82K
|
Health Technology
|
| O: 5.0%
H: 0.0%
C: -0.57%
ERAS | $1.79 0.0% 570K
|
|
| O: 0.0%
H: 2.59%
C: -3.7%
NVS | $94.36 1.93% 0.0% 2.3M
|
Health Technology
|
| O: 4.24%
H: 0.68%
C: -0.77%
melanoma publication potential
Global Pancreatic Cancer Competitive Landscape Report 2023: Comprehensive Insights about 250+ Companies and 300+ Drugs
Published: 2023-05-08 (Crawled : 15:00) - prnewswire.com
NVS | $94.36 1.93% 0.0% 2.3M
|
Health Technology
|
| O: -0.11%
H: 0.72%
C: 0.3%
TCRR 4 | $1.48 3.38% 3.9M
|
Health Technology
|
| O: 6.91%
H: 1.49%
C: -2.49%
INCY | $52.3 -0.98% -0.99% 2.2M
|
Health Technology
|
| O: 0.03%
H: 0.17%
C: -1.19%
BNTX | $86.82 0.75% 0.75% 1.6M
|
Health Technology
|
| O: 4.23%
H: 0.0%
C: -4.4%
ADAP | $0.97 7.97% 7.38% 1.5M
|
Health Technology
|
| O: 1.43%
H: 2.11%
C: -1.41%
companies report cancer pancreatic global
Novartis delivers continued strong momentum of key growth brands, progress on strategic initiatives and confirms FY’22 Group guidance
Published: 2022-07-19 (Crawled : 06:00) - globenewswire.com
NVSEF | $93.6375 6.88% 82K
|
Health Technology
|
| O: 3.55%
H: 0.0%
C: -0.01%
NVS | $94.36 1.93% 0.0% 2.3M
|
Health Technology
|
| O: 4.22%
H: 0.26%
C: -0.22%
novartis momentum growth group
Breast Cancer Therapeutics Market 2023, USD 15.64 billion Growth is Expected between 2023 to 2028, Robust pipeline and new drug approvals to Boost Growth - Technavio
Published: 2024-01-30 (Crawled : 18:00) - prnewswire.com
GLAXF | News | $20.2 -14.18% 510
|
Health Technology
|
| O: 5.68%
H: 0.77%
C: 0.77%
AZNCF | News | $138.24 -4.19% 800
|
Health Technology
|
| O: 3.41%
H: 0.0%
C: -2.45%
VTRS A | $11.25 1.17% 1.16% 4.7M
|
Health Technology
|
| O: -0.08%
H: 3.47%
C: -0.25%
NVS | $94.36 1.93% 0.0% 2.3M
|
Health Technology
|
| O: -2.04%
H: 0.19%
C: -1.97%
GSK | News | $39.75 1.22% 0.0% 1.6M
|
Health Technology
|
| O: 4.04%
H: 1.57%
C: -3.02%
ABBV | $166.41 1.06% 0.0% 5.5M
|
Health Technology
|
| O: 0.5%
H: 0.07%
C: -0.81%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: 1.75%
H: 0.0%
C: 0.0%
PBYI | $5.01 0.4% 0.4% 290K
|
Health Technology
|
| O: -0.1%
H: 2.31%
C: -1.26%
AZN | News | $68.56 0.29% 0.29% 4.7M
|
Health Technology
|
| O: 0.82%
H: 0.12%
C: -1.64%
AMGN | $269.03 2.39% 2.33% 3.4M
|
Health Technology
|
| O: 0.44%
H: 0.2%
C: -0.55%
drug breast expected cancer pipeline therapeutics growth market
Topical Corticosteroids Market to Grow by USD 1.08 billion between 2022 to 2027, globally at 4% CAGR - Technavio
Published: 2024-01-30 (Crawled : 23:00) - prnewswire.com
ALPMF | $9.17 43.47% 16K
|
Health Technology
|
| O: 4.34%
H: 0.0%
C: 0.0%
GLAXF | News | $20.2 -14.18% 510
|
Health Technology
|
| O: 5.68%
H: 0.77%
C: 0.77%
AZNCF | News | $138.24 -4.19% 800
|
Health Technology
|
| O: 3.41%
H: 0.0%
C: -2.45%
ALPMY | $9.47 -1.11% 520K
|
Manufacturing
|
| O: 0.0%
H: 1.38%
C: 0.26%
VTRS A | $11.25 1.17% 1.16% 4.7M
|
Health Technology
|
| O: -0.08%
H: 3.47%
C: -0.25%
NVS | $94.36 1.93% 0.0% 2.3M
|
Health Technology
|
| O: -2.04%
H: 0.19%
C: -1.97%
GSK | News | $39.75 1.22% 0.0% 1.6M
|
Health Technology
|
| O: 4.04%
H: 1.57%
C: -3.02%
ABBV | $166.41 1.06% 0.0% 5.5M
|
Health Technology
|
| O: 0.5%
H: 0.07%
C: -0.81%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: 1.75%
H: 0.0%
C: 0.0%
AZN | News | $68.56 0.29% 0.29% 4.7M
|
Health Technology
|
| O: 0.82%
H: 0.12%
C: -1.64%
market
Lupus Nephritis Market to Extend at a CAGR of 8.4% by 2032 | DelveInsight
Published: 2022-06-06 (Crawled : 16:00) - prnewswire.com
NVSEF | $93.6375 6.88% 82K
|
Health Technology
|
| O: -1.87%
H: 2.91%
C: 2.91%
NVS | $94.36 1.93% 0.0% 2.3M
|
Health Technology
|
| O: 0.31%
H: 0.0%
C: -1.04%
LLY | News | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: 3.83%
H: 0.0%
C: 0.0%
OMER | $3.045 -5.14% -5.42% 390K
|
Health Technology
|
| O: 0.8%
H: 2.78%
C: -13.1%
lupus market
Incyte Announces European Commission Approval of Jakavi® (ruxolitinib) as the First Post-Steroid Treatment for Acute and Chronic Graft-Versus-Host Disease
Published: 2022-05-05 (Crawled : 10:00) - biospace.com/
NVS | $94.36 1.93% 0.0% 2.3M
|
Health Technology
|
| O: -0.39%
H: 0.15%
C: -1.07%
INCY | $52.3 -0.98% -0.99% 2.2M
|
Health Technology
|
| O: 3.73%
H: 0.09%
C: -3.98%
jakavi treatment disease approval
Global Microarray Market Report 2022: Large-Scale DNA/Gene Chip Initiatives to Drive Sector Moving Forward
Published: 2022-11-09 (Crawled : 21:00) - prnewswire.com
NVS | $94.36 1.93% 0.0% 2.3M
|
Health Technology
|
| O: 2.81%
H: 0.43%
C: -0.2%
MDT | $79.48 0.37% -0.29% 6.7M
|
Health Technology
|
| O: 3.56%
H: 0.11%
C: -0.33%
ABBV | $166.41 1.06% 0.0% 5.5M
|
Health Technology
|
| O: 2.06%
H: 0.0%
C: -0.62%
ABT | News | $107.28 1.91% 0.18% 10M
|
Health Technology
|
| O: 3.59%
H: 1.37%
C: 1.16%
global report chip market
Global Hairy Cell Leukemia Market Analysis & Forecast 2024-2034
Published: 2024-02-02 (Crawled : 03:00) - prnewswire.com
NVS | $94.36 1.93% 0.0% 2.3M
|
Health Technology
|
| O: -0.5%
H: 0.26%
C: -1.03%
JNJ | News | $147.91 1.49% -0.03% 9.6M
|
Health Technology
|
| O: -0.15%
H: 0.0%
C: 0.0%
BMY | $48.93 1.3% 0.0% 10M
|
Health Technology
|
| O: 1.23%
H: 1.5%
C: -1.14%
ABBV | $166.41 1.06% 0.0% 5.5M
|
Health Technology
|
| O: 3.59%
H: 0.0%
C: 0.0%
AMGN | $269.03 2.39% 2.33% 3.4M
|
Health Technology
|
| O: -0.28%
H: 0.66%
C: -0.14%
cell global leukemia market
Psoriasis Treatment Market Players Observe Rising Trend of Personalized Medicines, According to TMR Report
Published: 2022-06-24 (Crawled : 12:00) - prnewswire.com
AZNCF | News | $138.24 -4.19% 800
|
Health Technology
|
| O: 0.64%
H: 4.18%
C: 1.33%
NVSEF | $93.6375 6.88% 82K
|
Health Technology
|
| O: 6.71%
H: 0.0%
C: -0.1%
PFE A | $26.0 2.4% -0.15% 38M
|
Health Technology
|
| O: 2.96%
H: 0.0%
C: 0.0%
NVS | $94.36 1.93% 0.0% 2.3M
|
Health Technology
|
| O: 2.38%
H: 0.0%
C: 0.0%
JNJ | News | $147.91 1.49% -0.03% 9.6M
|
Health Technology
|
| O: 1.94%
H: 0.0%
C: 0.0%
LLY | News | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: 3.32%
H: 0.0%
C: 0.0%
AZN | News | $68.56 0.29% 0.29% 4.7M
|
Health Technology
|
| O: 4.41%
H: 0.0%
C: 0.0%
treatment report psoriasis market
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
Your saved searches
Save your searches and get alerts when important news are released.